Fumitory

Metadata

• Common Names: Fumitory, Earth Smoke (English); Erdrauch, Gemeiner Erdrauch (German); Fumeterre (French); Fumaria (Italian/Spanish)
• Botanical Name: Fumaria officinalis L.
• Plant Family: Papaveraceae (formerly classified in Fumariaceae)
• Part Used: Aerial parts (Fumariae herba), collected during flowering
• Evidence Quality Rating: Very Preliminary (Commission E, ESCOP, and EMA traditional use approval; but very limited modern clinical trial data)

Approved Indications

Commission E

• Colicky pain affecting the gallbladder and biliary system, together with the gastrointestinal tract
• Documented choleretic and spasmolytic activity

ESCOP

• Digestive complaints due to hepatobiliary disturbance, including stomach ache, nausea, vomiting, sensation of fullness, and flatulence
• The ESCOP monograph (2018) cites pharmacological studies in humans demonstrating normalization of bile flow and controlled clinical studies in patients with biliary disorders of various origin

EMA/HMPC

• Traditional use: To increase the flow of bile for the relief of symptoms of indigestion such as sensation of fullness, flatulence, and slow digestion
• Classified as a traditional herbal medicinal product under Directive 2004/24/EC (traditional use registration); the HMPC considered available data insufficient to grant “well-established use” status
• First community herbal monograph adopted in 2011 (EMA/HMPC/574766/2010), revised subsequently
• Not recommended for children and adolescents under 18 years of age

Agreement/Disagreement Between Bodies

• All three bodies agree on the hepatobiliary and digestive indication as the primary therapeutic use
• Commission E is the most specific, focusing on colicky biliary and GI pain with an implied spasmolytic effect
• ESCOP provides the broadest indication, covering a wider range of dyspeptic symptoms attributable to hepatobiliary disturbance
• The EMA is the most conservative, limiting fumitory to traditional use status for increasing bile flow and relieving indigestion
• All bodies agree that the amphocholeretic (bile-normalizing) property is the central pharmacological feature
• Fumitory was rejected from the EU Community List due to the lack of adequate toxicological studies, though the HMPC monograph remains in place

Conditions Treated

Primary

• Biliary dyskinesia (functional biliary motility disorders)
• Colicky pain of the gallbladder and bile ducts
• Spastic complaints of the upper gastrointestinal tract

Secondary

• Functional dyspepsia (sensation of fullness, bloating, flatulence, nausea)
• Hepatobiliary insufficiency with impaired bile flow
• Post-cholecystectomy digestive complaints

Traditional/Historical

• Fumitory has been used medicinally for over 2,000 years. Dioscorides (De Materia Medica, 1st century AD) wrote that “the plant drives bile through the urine when eaten.” Pliny the Elder recorded similar uses in Naturalis Historia
• Galen agreed with Dioscorides on its bile-driving properties, and subsequent European herbalists including Macer, Fuchs, Dodoens, and Bauhin continued the tradition
• Nicholas Culpeper (17th century) valued fumitory for skin conditions, recommending the juice mixed with dock for “scabs, pimples, blotches, wheals, and pushes”
• Traditional European use as a “blood purifier” (depurative) and for skin conditions (eczema, psoriasis, scabies)
• Traditional use as a mild diuretic and laxative
• The name “fumitory” derives from the Latin fumus terrae (“smoke of the earth”), referring to the smoky grey-blue appearance of the foliage and the translucent quality of its flowers, giving the impression of smoke rising from the ground

Mechanism of Action

Isoquinoline Alkaloids (total content approximately 0.4-1.3% of dried herb)

• Protopine (0.04-0.25% of dried herb; protoberberine-type alkaloid): The pharmacologically most significant constituent. Protopine is responsible for the distinctive amphocholeretic effect — it normalizes bile flow in both directions, increasing bile secretion when it is abnormally low and decreasing it when it is abnormally elevated. In animal experiments, protopine had no effect on normal choleresis but significantly modified bile flow that was artificially increased or decreased. This bidirectional bile-regulating property distinguishes fumitory from simple choleretics like artichoke. Protopine also has a contractile action on the sphincter of Oddi in animal models, and exerts spasmolytic effects on smooth muscle of the GI tract at concentrations of 0.5-5.0 mcg/mL, with relaxation activity approximately equipotent to papaverine in isolated guinea pig and rabbit ileum preparations. Additional pharmacological properties include antihistaminic, hypotensive, bradycardic, and mild sedative activities at low doses
• Fumariline (spirobenzylisoquinoline-type): Present in small quantities (approximately 3 mg/100 g dry weight); contributes to the overall spasmolytic activity of the whole extract
• Cryptopine (approximately 11 mg/100 g dry weight): Minor protoberberine alkaloid with smooth muscle relaxant properties
• Parfumine (spirobenzylisoquinoline-type): Present at approximately 2 mg/100 g dry weight
• Sanguinarine and other benzophenanthridine alkaloids: Present in trace amounts; antibacterial properties
• Stylopine, sinactine, fumaritine, fumarophycine: Minor alkaloids contributing to the overall pharmacological profile

Other Constituents

• Fumaric acid: An organic acid also found in the plant; has been investigated independently for anti-inflammatory and immunomodulatory effects
• Malic acid: Organic acid contributing to the bitter taste
• Flavonoids (including rutin and quercetin glycosides): Antioxidant and mild anti-inflammatory activity
• Mucilage and tannins: Minor constituents

Hepatoprotective Effects

• In animal studies, isolated protopine at doses of 10-20 mg p.o. demonstrated hepatoprotective effects comparable to silymarin (25 mg p.o.) against experimentally induced liver damage (PMID: 18164606, though this study used Fumaria indica protopine, the alkaloid is structurally identical)

Summary of Key Mechanisms

1. Amphocholeretic action (protopine): Normalizes bile flow — the pharmacological highlight
2. Spasmolytic action (protopine, fumariline, whole extract): Relaxes smooth muscle of bile ducts, sphincter of Oddi, and GI tract
3. Hepatoprotective action (protopine, fumaric acid): Protects hepatocytes from oxidative damage in animal models
4. Mild diuretic and laxative effects (traditional observation, mechanism not well characterized)

Clinical Evidence Summary

The clinical evidence for fumitory is very limited by modern standards. Despite Commission E, ESCOP, and EMA recognition, the available clinical trial data is sparse and largely derived from older, methodologically limited studies.

Biliary Disorders

• Double-blind, placebo-controlled trial (n=30): Patients with various biliary disorders (dyskinesia, cholecystitis, hepatopathy, cholelithiasis, post-cholecystectomy syndrome) received Fumaria-Nebulisat (water extract 4-6:1), 250 mg tablets, 3 tablets daily for 28 days. The study reported successful results for all 30 patients, with particular improvement in symptoms of fullness and flatulence. Safety and tolerability were described as proven. However, the very small sample size and limited methodological reporting severely constrain the strength of this evidence
• Open clinical study (n=105): A larger uncontrolled study in patients with biliary disorders of various origin (hepatopathy, cholelithiasis, post-cholecystectomy syndrome) reported favourable results, with overall symptom improvement rated as excellent or good. The lack of a control group and blinding limits the interpretability of these findings
• Hentschel et al. (1995) reviewed the clinical literature and concluded that while there are very few studies supporting dermatological, diuretic, or laxative indications, the use for functional diseases of the biliary system has more support, though still insufficient by modern evidence standards (PMID: 7672742)

Irritable Bowel Syndrome

• Brinkhaus et al. (2005): In a well-designed randomized, double-blind, placebo-controlled trial (n=106), IBS patients received Fumaria officinalis 1500 mg daily, Curcuma xanthorrhiza 60 mg daily, or placebo for 18 weeks. IBS-related pain decreased by -0.9 +/- 11.5 mm in the fumitory group compared with -0.3 +/- 9.9 mm in the placebo group (p=0.81). Distension actually increased slightly in the fumitory group. Neither fumitory nor curcuma showed any therapeutic benefit over placebo for IBS (PMID: 16173134). This is the most rigorous trial of fumitory and it was negative, though IBS is not the same as the traditional biliary indication

Pharmacological Studies in Humans

• Pharmacological studies in humans have demonstrated effects on choleresis and normalization of bile flow, supporting the amphocholeretic concept
• Tolerability in human studies has been consistently described as very good, with only minor adverse events reported

Evidence Gaps (Transparency Statement)

• No modern, large-scale, rigorous RCTs exist for fumitory monotherapy in its primary indication (biliary dyskinesia or colicky biliary/GI pain)
• The only well-designed RCT (Brinkhaus 2005) tested fumitory in IBS rather than biliary dyskinesia, and it was negative
• The existing positive biliary studies are small, older, and methodologically limited
• The amphocholeretic effect is primarily demonstrated in animal models; human pharmacological data is supportive but limited
• The Commission E approval and ESCOP recognition were based substantially on pharmacological plausibility and traditional use rather than robust clinical trial data
• There is a clear need for modern, adequately powered clinical trials in biliary dyskinesia and functional dyspepsia

Safety Profile

Contraindications

• Bile duct obstruction: Any herb that modifies bile flow is contraindicated in the presence of biliary obstruction
• Gallstones: Use only under medical supervision; stimulation of bile flow could theoretically provoke gallstone movement
• Known hypersensitivity to fumitory or other members of Papaveraceae
• Bile duct inflammation (cholangitis): Avoid during acute inflammatory conditions of the biliary system
• Severe liver disease: Insufficient safety data; use with caution or avoid

Drug Interactions

• No clinically documented drug interactions have been reported
• Theoretical concern: protopine has mild hypotensive and bradycardic effects at higher doses in animal studies; use with caution alongside antihypertensive or bradycardia-inducing medications, though this has not been observed clinically at therapeutic doses
• No known interactions with anticoagulants, oral contraceptives, or other commonly prescribed drugs

Side Effects

• Generally well tolerated at recommended doses
• In one clinical study, adverse effects occurred in up to 69% of patients, with GI complaints (56%) and flushing (31%) being the most common — however, this was a single study and other studies report much lower adverse event rates
• At excessive doses or prolonged use: severe diarrhea, muscle cramps, and breathlessness have been reported (toxicity concern at supratherapeutic doses)
• Dermatitis or skin irritation possible from direct contact with fresh plant material (rare)
• The alkaloids may exhibit dose-dependent effects: hypotensive at low doses, potentially causing excitation and convulsions at very high doses (animal data; not expected at therapeutic doses in humans)

Pregnancy/Lactation

• Pregnancy: No adequate safety data available; avoid use due to the presence of isoquinoline alkaloids and insufficient safety documentation
• Lactation: No safety data; avoid use
• Children and adolescents: Not recommended for use in those under 18 years due to lack of evidence (per EMA/HMPC)

Duration of Use

• The EMA/HMPC recommends use for a maximum of 2 weeks; if symptoms persist beyond 2 weeks, medical consultation is advised
• Prolonged continuous use should be avoided due to insufficient long-term safety data

Clinical Dosage

Forms and Ranges

• Dried herb (tea/infusion): 2-3 g of comminuted dried aerial parts per 150 mL boiling water, steeped 10-15 minutes, strained; drink one cup several times daily before or with meals
• Daily dose of dried herb: 6 g per day (Commission E)
• Dry extract (DER 4-6:1, water): 250 mg, 3 times daily (as used in clinical studies; Fumaria-Nebulisat)
• Tincture (1:5): 1-2 mL, three times daily
• Powdered herb (capsules): Up to 1,100 mg per day (in divided doses)
• Pressed juice from fresh herb: 6-8 mL daily (traditional preparation)

Timing and Duration

• Take before or with meals to maximize choleretic and digestive effects
• Limit use to 2 weeks unless otherwise directed by a healthcare professional (per EMA recommendation)
• If symptoms persist or worsen after 2 weeks, seek medical evaluation

Pharmacopoeia Standards

• Fumariae herba is described in the European Pharmacopoeia (Ph. Eur.)
• Quality specifications include minimum total alkaloid content requirements (expressed as protopine)
• Commercial supply is primarily sourced from wild collection in Eastern Europe

Sources

• Commission E Monograph: Fumariae herba (Erdrauchkraut). Bundesanzeiger, 1990
• ESCOP Monographs Online Series: Fumariae herba (Fumitory). Exeter: ESCOP; 2018
• EMA/HMPC Community Herbal Monograph on Fumaria officinalis L., herba (EMA/HMPC/574766/2010; Revision 1)
• EMA/HMPC Assessment Report on Fumaria officinalis L., herba (EMA/HMPC/576232/2010)
• Hentschel C, Dressler S, Hahn EG. Fumaria officinalis (fumitory)—clinical applications. Fortschr Med. 1995;113(19):291-292. PMID: 7672742
• Brinkhaus B, et al. Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol. 2005;40(8):936-943. PMID: 16173134
• Rathi SG, et al. Hepatoprotective potential of Fumaria indica Pugsley whole plant extracts, fractions and an isolated alkaloid protopine. Phytomedicine. 2008;15(6-7):470-477. PMID: 18164606
• Sousek J, et al. Alkaloids and organic acids content of eight Fumaria species. Phytochem Anal. 1999;10:6-11
• Suau R, et al. Direct determination of alkaloid contents in Fumaria species by GC-MS. Phytochem Anal. 2002;13(6):363-367. PMID: 12494757
• Arzneipflanzenlexikon: Erdrauch (arzneipflanzenlexikon.info)
• British Herbal Pharmacopoeia: Fumariae herba

Connections

• Related to Artichoke as a choleretic herb for hepatobiliary complaints, though artichoke acts as a simple choleretic (stimulates bile) while fumitory uniquely acts as an amphocholeretic (normalizes bile in both directions)
• Compare with Celandine (greater celandine, Chelidonium majus), another Papaveraceae member with choleretic and spasmolytic properties; both contain isoquinoline alkaloids, but celandine carries more significant hepatotoxicity concerns
• Related to Boldo as a traditional choleretic and antispasmodic herb for biliary complaints, sharing both the Commission E approved indication and the challenge of limited clinical evidence
• Compare with Gentian and Wormwood as bitter digestive tonics, though fumitory acts primarily through alkaloid-mediated bile normalization and spasmolysis rather than the bitter-reflex mechanism
• Fumitory’s amphocholeretic property is pharmacologically distinctive among hepatobiliary herbs: while most choleretics simply increase bile flow, fumitory’s protopine normalizes bile flow bidirectionally, making it theoretically suited for conditions where bile flow may be either insufficient or excessive
• Part of the broader European tradition of hepatobiliary phytotherapy, a therapeutic category not widely recognized in US gastroenterology practice